Werewolf Therapeutics, Inc.
NASDAQ:HOWLBiotechnology
Healthcare
$1.03 +6.12%
+$0.06 today
- Market cap
- $50.06M
- Beta
- 0.29
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.71
52W Low $0.27High $1.83
Volume 1.85M
Average 5.09M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$60.68M
FY 2025 · Annual
Net Income
-$60.82M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 16.4M | 19.94M | 1.89M | 0 |
| Cost of Revenue | 0 | 2.51M | 1.76M | 1.81M | 1.63M |
| Gross Profit | 0 | 13.89M | 18.18M | 71K | (1.63M) |
| Gross Margin | — | 84.7% | 91.2% | 3.8% | — |
| Research & Development | 35.27M | 53.76M | 41.78M | 56.43M | 44.83M |
| Selling, General & Admin | 14.82M | 21.5M | 18.67M | 19.05M | 15.85M |
| Operating Expenses | 50.09M | 69.95M | 58.68M | 73.67M | 59.04M |
| Depreciation & Amortization | 216K | 1.1M | 1.76M | 1.81M | 1.63M |
| EBITDA | (49.77M) | (52.71M) | (32.47M) | (64.05M) | (53.91M) |
| EBITDA Margin | — | -321.4% | -162.8% | -3397.6% | — |
| Operating Income | (50.09M) | (56.06M) | (40.5M) | (73.59M) | (60.68M) |
| Operating Margin | — | -341.8% | -203.1% | -3904.2% | — |
| Interest Income | 104K | 1.91M | 7.42M | 6.67M | 3.11M |
| Interest Expense | 0 | 0 | 3.14M | 4.66M | 5.27M |
| Other Income / Expenses | 104K | 2.25M | 3.14M | 3.08M | (145K) |
| Income Before Tax | (49.98M) | (53.81M) | (37.37M) | (70.52M) | (60.82M) |
| Pre-Tax Margin | — | -328.1% | -187.4% | -3740.8% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.98M) | (53.81M) | (37.37M) | (70.52M) | (60.82M) |
| Net Margin | — | -328.1% | -187.4% | -3740.8% | — |
| EPS (Basic) | (10.94) | (1.86) | (1.05) | (1.63) | (1.32) |
| EPS (Diluted) | (10.94) | (1.86) | (1.05) | (1.63) | (1.33) |
| 18.46M | 28.86M | 35.65M | 43.33M | 46.02M | |
| 18.46M | 28.86M | 35.65M | 43.86M | 46.81M |
HOWL Earnings Waterfall · TTM
NASDAQ:HOWL · Revenue to Net Income
Key Ratios
EPS$-0.73
Gross Margin22.1%
Net Margin4.4%
P/E Ratio-0.5
P/S Ratio0.2
Analysis
$21.0M of revenue converted into -$34.6M of net income for the selected period. Gross margin is 22.1% and net margin is 4.4%, showing how much revenue survives after costs and taxes. EPS is $-0.73, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 16, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| EFFECT | EFFECT filing | Nov 12, 2026 | |
| 424B3 | 424B3 filing | Nov 12, 2026 | |
| S-4/A | S-4/A filing | Nov 10, 2026 |
How much revenue does HOWL generate?
Werewolf Therapeutics, Inc. (HOWL) reported $0.00 of revenue in fiscal 2025.
Is HOWL profitable?
Werewolf Therapeutics, Inc. (HOWL) reported -$60.82M of net income.
Continue the stock analysis
Jump to another research area for this company.